Dr. Georges M. Halpern Joins Advitech Scientific Advisory Board: Leading Scientist is Internationally Recognized for His Work in Immunology.QUEBEC CITY, Quebec -- Renaud Beauchesne, President and Chief Executive Officer of Advitech (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. ), announced today the appointment of Dr. Georges M. Halpern, MD, PhD, to its Scientific Advisory Board. Advitech is a Canadian biotech company currently involved in developing a new oral treatment for psoriasis for which it has just received positive results without undesirable side effects Side effects Effects of a proposed project on other parts of the firm. after 16 weeks of a clinical trial. "It is an honour and pleasure to welcome Dr Halpern to our group of distinguished scientific advisors," stated Renaud Beauchesne. "Advitech is pursuing the development of novel therapies targeting auto-immune disorders and Dr Halpern's expertise in immunology combined with his outstanding scientific expertise will undoubtedly benefit our company. We will also seek his advice on our current XP-828L program, a growth-factor based oral treatment for psoriasis, as we enter our second clinical study on its safety and efficacy from which we expect to have results by the second quarter of 2005." Professor Emeritus of Medicine, University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). Davis, Dr. Halpern is currently Distinguished Professor of Pharmaceutical Sciences at the Hong Kong Polytechnic University The Hong Kong Polytechnic University (Abbreviated:PolyU or HKPU Traditional Chinese: 香港理工大學 and Honorary Professor of Pharmacology at the University of Hong Kong The University of Hong Kong (commonly abbreviated as HKU, pronounced as "Hong Kong U") is the oldest tertiary institution in Hong Kong. Its motto is "Sapientia et Virtus" in Latin, and " . Dr Halpern has worked and lectured in 76 countries. He is recognized worldwide for his many contributions to the field of medicine and is an internationally recognized authority on allergies, asthma, immunology, nutrition, and alternative medicine. Dr. Halpern is also the author of over 150 scientific publications. He resides in Portola Valley, California Portola Valley is an incorporated town in San Mateo County, California, United States. The population was 4,462 at the 2000 census. It was named for Spanish explorer Gaspar de Portola, who led the first party of Europeans to explore the San Francisco Peninsula, in 1769. . Born a French citizen in Warsaw, Poland, he was raised in Paris, where he attended the Sorbonne. From there he went on to receive his medical degree from the Faculty of Medicine of Paris. He received his PhD DSc degree, with highest honors and jury honors, from the Faculty of Pharmacy, University of Paris-South. Dr. Halpern is a Fellow of the Royal Society Fellow of the Royal Society is an honour accorded to distinguished scientists and a category of membership of the Royal Society. Fellows are entitled to put the letters FRS after their name. Up to 44 new fellows are elected each year by ballot of the existing fellows. of Medicine (London) and of 26 other prestigious national, foreign and international academies and scientific societies. Georges M. Halpern is the author of seventeen books and 56 book chapters and has published 138 original papers and hundreds of reviews and abstracts. Dr. Halpern has been and continues to be very active as a consultant for governmental, national and international agencies on public health issues and infectious diseases as well as asthma and allergic conditions. He also does consulting for pharmaceutical, diagnostic and nutraceutical companies, as well as for the food, wine, and water industries. In 1985, he was awarded the Medal of Vermeil ver·meil n. 1. Vermilion or a similar bright red color. 2. Gilded silver, bronze, or copper. adj. Bright red in color. by the City of Paris for his outstanding contributions to medicine, dedication to patients, and personal achievements. About Advitech Advitech specializes in the development of bioactive products derived from milk proteins. Its key focus areas are in the fields of immunology and inflammatory processes. Its main platform, XP-828L, is a bioactive complex used in the development of an oral treatment for psoriasis and other immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. disorders. Psoriasis affects between 2-3% of the global population and more than 6 million adults in North America alone. Advitech has 15 employees, with more than half of them engaged in research and development activities at its facility at Universite Laval in Quebec City. Advitech's common shares are listed on the TSX Venture exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. under the symbol AVI. The number of common shares outstanding is 54,723,627. This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward- looking statements. The TSX Venture Exchange Inc. has neither approved nor disapproved the contents of this press release. Advitech Inc. (TSX VENTURE:AVI) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion